Primaquine Mechanism of Action
Primaquine eliminates tissue (exoerythrocytic/hypnozoite) forms of malaria parasites in the liver, preventing relapses in P. vivax and P. ovale malaria, and is also active against P. falciparum gametocytes to block transmission. 1
Primary Mechanism: Tissue Stage Activity
Primaquine is an 8-aminoquinoline compound that specifically targets the dormant liver forms (hypnozoites) of P. vivax and P. ovale that persist after blood-stage parasites are cleared 1. This tissue-stage activity is what distinguishes primaquine from blood schizontocidal drugs like chloroquine or artemisinin compounds, which only kill parasites circulating in red blood cells 1.
The drug achieves "radical cure" by eradicating these exoerythrocytic parasites that would otherwise cause relapses weeks to months after initial treatment 1. Clinical evidence demonstrates an 80% risk reduction of relapse when primaquine is prescribed for P. vivax malaria 2.
Secondary Mechanism: Gametocytocidal Activity
Primaquine also acts against sexual-stage parasites (gametocytes) of P. falciparum, which are responsible for transmission to mosquitoes 1. Even at single low doses (0.25 mg/kg), primaquine rapidly sterilizes gametocytes and prevents mosquito infectivity 3. This transmission-blocking effect occurs through a dose-dependent gametocytocidal mechanism that precedes actual parasite clearance 3.
Molecular Mechanism: Two-Step Biochemical Process
At the molecular level, primaquine operates through a complex two-step relay 4:
- Step 1: Primaquine requires hepatic metabolism by CYP2D6 to form hydroxylated metabolites (OH-PQm)
- Step 2: These metabolites are then reduced by cytochrome P450 NADPH:oxidoreductase (CPR) in liver and bone marrow, generating quinoneimine compounds that produce excessive hydrogen peroxide (H₂O₂), leading to parasite death 4
This explains why primaquine efficacy depends on host CYP2D6 metabolizer status and why the drug's potency against gametocytes is enhanced approximately 1000-fold in the presence of CPR 4.
Additional Proposed Mechanisms
Research suggests primaquine may also:
- Target iron-sulfur (Fe-S) cluster proteins in mitochondria through oxidative stress, particularly affecting enzymes like aconitase 5
- Disrupt mitochondrial function by causing membrane potential loss, cytochrome c leakage, and ROS overproduction 6
- Inhibit protein biosynthesis in susceptible organisms 7
Critical Clinical Caveat
The major limiting factor for primaquine use is the risk of severe hemolytic anemia in patients with G6PD deficiency 2. G6PD testing is mandatory before treatment. For patients with intermediate G6PD deficiency (30-70% activity, non-Mediterranean variant), a modified weekly dosing regimen (45 mg once weekly for 8 weeks) can be used with close monitoring 2. Primaquine is absolutely contraindicated in pregnancy and breastfeeding 2.